Details:
NTC and I-MED Pharma’s successful collaboration to bring I-DEFENSE® innovative ophthalmic ointment first to Canada and now to the U.S.A. is a testament to the dedication of both companies to advancing the science of dry eye.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Ophthalmology Product Name: I-Defense
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: I-MED
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 15, 2021